Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease

被引:0
作者
Kim, Jae Young [1 ,2 ]
Lim, Hyunsun [3 ]
Park, Cheol Ho [2 ]
Kim, Hyung Woo [2 ]
Chang, Tae Ik [1 ]
Han, Seung Hyeok [2 ]
机构
[1] Natl Hlth Insurance Serv Ilsan Hosp, Dept Internal Med, Goyang Si, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[3] Natl Hlth Insurance Serv Ilsan Hosp, Dept Res & Anal, Goyang Si, South Korea
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年 / 20卷 / 03期
关键词
cardiovascular disease; CKD; NATIONAL-HEALTH INSURANCE; PROTON-PUMP INHIBITORS; PRIMARY PREVENTION; SUBGROUP ANALYSIS; TASK-FORCE; OUTCOMES; ASSOCIATION; MORTALITY; DATABASE; EVENTS;
D O I
10.2215/CJN.0000000619
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Key PointsThe association between aspirin use and risk of the first cardiovascular event was NS in patients with CKD.Compared with nonusers, aspirin users had an increased risk of significant bleeding events.Aspirin prescription for the primary prevention of cardiovascular disease in patients with CKD needs careful consideration.BackgroundDespite the high cardiovascular risk in patients with CKD, the role of aspirin in primary prevention remains unclear. This study aimed to investigate the association between aspirin initiation in adults with CKD without prior cardiovascular disease (CVD) and the first cardiovascular and bleeding events using Korean nationwide cohort data.MethodsAmong individuals aged 40-79 years with an eGFR between 15 and 59 ml/min per 1.73 m2 who underwent routine health examinations between 2011 and 2016, 15,861 individuals who were newly prescribed aspirin at a dose of 100 mg/d were matched with 79,305 aspirin non-users by propensity score matching. The primary efficacy outcome was a composite of nonfatal atherosclerotic CVD or cardiovascular death. The primary safety outcome was hospitalization due to intracranial or gastrointestinal bleeding.ResultsDuring a mean follow-up of 6.9 +/- 2.9 years, the incidence rates for the primary efficacy outcome in aspirin users and nonusers were 8.0 and 9.0 per 1000 person-years, respectively. Aspirin therapy initiation was not associated with the primary efficacy outcome (hazard ratio, 0.93; 95% confidence intervals, 0.86 to 1.04). However, the primary safety outcome of major bleeding was more frequent in aspirin users than in nonusers (6.7 versus 4.7 per 1000 person-years). The hazard ratio for this outcome in aspirin users versus nonusers was 1.45 (95% confidence intervals, 1.32 to 1.59).ConclusionsNo association was observed between aspirin use and the risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding.
引用
收藏
页码:387 / 396
页数:10
相关论文
共 39 条
  • [1] Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1016/j.jacc.2019.03.010, 10.1161/CIR.0000000000000677, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.009]
  • [2] Australia and New Zealand Dialysis and Transplant Registry, 2019, The 42nd Annual Report 2019 (Data to 2018)
  • [3] Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy
    Baaten, Constance C. F. M. J.
    Schroer, Jonas R.
    Floege, Jurgen
    Marx, Nikolaus
    Jankowski, Joachim
    Berger, Martin
    Noels, Heidi
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (01): : 155 - 170
  • [4] Clopidogrel with or without Omeprazole in Coronary Artery Disease.
    Bhatt, Deepak L.
    Cryer, Byron L.
    Contant, Charles F.
    Cohen, Marc
    Lanas, Angel
    Schnitzer, Thomas J.
    Shook, Thomas L.
    Lapuerta, Pablo
    Goldsmith, Mark A.
    Laine, Loren
    Scirica, Benjamin M.
    Murphy, Sabina A.
    Cannon, Christopher P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) : 1909 - 1917
  • [5] Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
    Bowman, Louise
    Mafham, Marion
    Wallendszus, Karl
    Stevens, Will
    Buck, Georgina
    Barton, Jill
    Murphy, Kevin
    Aung, Theingi
    Haynes, Richard
    Cox, Jolyon
    Murawska, Aleksandra
    Young, Allen
    Lay, Michael
    Chen, Fang
    Sammons, Emily
    Waters, Emma
    Adler, Amanda
    Bodansky, Jonathan
    Farmer, Andrew
    McPherson, Roger
    Neil, Andrew
    Simpson, David
    Peto, Richard
    Baigent, Colin
    Collins, Rory
    Parish, Sarah
    Armitage, Jane
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (16) : 1529 - 1539
  • [6] Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease
    Cachofeiro, Victoria
    Goicochea, Marian
    Garcia de Vinuesa, Soledad
    Oubina, Pilar
    Lahera, Vicente
    Luno, Jose
    [J]. KIDNEY INTERNATIONAL, 2008, 74 : S4 - S9
  • [7] Aspirin Use to Prevent Cardiovascular Disease US Preventive Services Task Force Recommendation Statement
    Davidson, Karina W.
    Barry, Michael J.
    Mangione, Carol M.
    Cabana, Michael
    Chelmow, David
    Coker, Tumaini Rucker
    Davis, Esa M.
    Donahue, Katrina E.
    Jaen, Carlos Roberto
    Krist, Alex H.
    Kubik, Martha
    Li, Li
    Ogedegbe, Gbenga
    Pbert, Lori
    Ruiz, John M.
    Stevermer, James
    Tseng, Chien-Wen
    Wong, John B.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (16): : 1577 - 1584
  • [8] Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease
    Gallagher, Hugh
    Dumbleton, Jennifer
    Maishman, Tom
    Whitehead, Amy
    Moore, Michael, V
    Fuat, Ahmet
    Fitzmaurice, David
    Henderson, Robert A.
    Lord, Joanne
    Griffith, Kathryn E.
    Stevens, Paul
    Taal, Maarten W.
    Stevenson, Diane
    Fraser, Simon D.
    Lown, Mark
    Hawkey, Christopher J.
    Roderick, Paul J.
    [J]. TRIALS, 2022, 23 (01)
  • [9] Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
    Gaziano, J. Michael
    Brotons, Curios
    Coppolecchia, Rosa
    Critelli, Claudio
    Darius, Harald
    Gorelick, Philip B.
    Howard, George
    Pearson, Thomas A.
    Rothwell, Peter M.
    Miguel Ruilope, Luis
    Tendera, Michal
    Tognoni, Gianni
    [J]. LANCET, 2018, 392 (10152) : 1036 - 1046
  • [10] Glassock RJ, 2017, NAT REV NEPHROL, V13, P104, DOI [10.1038/nmeph.2016.163, 10.1038/nrneph.2016.163]